Skip to main content
Premium Trial:

Request an Annual Quote

More Bumps in the PGx Road

For years, Herceptin has been hailed as a major success in the tailored-medicine landscape. The breast cancer drug is prescribed to women who test positive for a gene or for certain levels of protein on the tumor. But new studies indicate that women who test negative for these things still benefit from taking Herceptin -- and experts say "as many as 40 percent of women with early breast cancer might benefit from the drug but are not getting it," according to this New York Times article.


The Scan

mRNA-Based Vaccine on the Way in China

China may soon have its own mRNA-based vaccine, according to Nature News.

Arranged Killing, Fraud Alleged by Prosecutors

The Wall Street Journal reports that prosecutors allege that the co-founder of a biotech arranged to have a business associate who threatened to expose him as a fraud killed.

Whirlwind Decade of CRISPR

The New York Times looks back at the 10 years since the University of California, Berkeley's Jennifer Doudna and her colleagues published their CRISPR paper.

PNAS Papers on Blue Cone Monochromacy Structural Variants, HIV-1 Mutant, T-ALL

In PNAS this week: structural variants linked to blue cone monochromacy, HIV-1 variants affecting the matrix protein p17, and more.